• Profile
Close

Effect of midodrine vs placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): An international randomised clinical trial

Intensive Care Medicine Sep 08, 2020

Santer P, Anstey MH, Patrocínio MD, et al. - Given that a need for intravenous vasopressor medications to maintain normotension commonly delays ICU discharge, and therefore, this multicentre, randomised, controlled trial was undertaken to investigate whether midodrine, an oral α1-adrenergic agonist, used as adjunct to standard treatment can shorten the duration of intravenous vasopressor need. Enrollment of adult patients with hypotension needing a single-agent intravenous vasopressor for ≥ 24 h was done. Patients were administered oral midodrine (20 mg) or placebo every 8 h in addition to standard care until cessation of intravenous vasopressors, ICU discharge, or development of adverse events. Findings revealed no accelerated liberation from intravenous vasopressors in relation to treatment with midodrine. Also, no effectiveness of midodrine was evident as a treatment option for hypotension in critically ill patients.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay